AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Mitochondrial import receptor subunit TOM6 homolog

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96B49

UPID:

TOM6_HUMAN

Alternative names:

Overexpressed breast tumor protein; Translocase of outer membrane 6 kDa subunit homolog

Alternative UPACC:

Q96B49; B2DG15; Q9UH52

Background:

The Mitochondrial import receptor subunit TOM6 homolog, known by its alternative names Overexpressed breast tumor protein and Translocase of outer membrane 6 kDa subunit homolog, plays a crucial role in the mitochondrial import machinery. This protein is essential for the translocation of preproteins across the outer mitochondrial membrane, facilitating their proper localization and function within the mitochondria.

Therapeutic significance:

Understanding the role of Mitochondrial import receptor subunit TOM6 homolog could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial dynamics suggests its involvement in cellular energy metabolism and apoptosis, making it a potential target for therapeutic intervention in diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.